Robert G. Shepler - 08 Jul 2025 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Role
Director
Signature
/s/ Robert G. Shepler
Issuer symbol
AKYA
Transactions as of
08 Jul 2025
Net transactions value
$0
Form type
4
Filing time
10 Jul 2025, 20:38:26 UTC
Previous filing
05 Jun 2024

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
SHEPLER ROBERT G Director C/O AKOYA BIOSCIENCES, INC., 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH /s/ Robert G. Shepler 10 Jul 2025 0001113663

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKYA Stock Option (Right to Buy) Other $0 -16,860 -100% $0.000000 0 08 Jul 2025 Common Stock 16,860 $21.95 Direct F1, F2
transaction AKYA Stock Option (right to buy) Other $0 -30,549 -100% $0.000000 0 08 Jul 2025 Common Stock 30,549 $11.24 Direct F1, F2
transaction AKYA Stock Option (right to buy) Other $0 -56,322 -100% $0.000000 0 08 Jul 2025 Common Stock 56,322 $5.70 Direct F1, F2
transaction AKYA Stock Option (right to buy) Other $0 -50,000 -100% $0.000000 0 08 Jul 2025 Common Stock 50,000 $2.01 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Robert G. Shepler is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Disposition of shares pursuant to that certain Amended and Restated Agreement and Plan of Merger dated as of April 28, 2025, as amended (the "Merger Agreement"), by and among Quanterix Corporation, a Delaware corporation ("Quanterix"), Wellfleet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Quanterix ("Merger Sub"), and Issuer. On July 8, 2025 (the "Closing Date"), Merger Sub merged with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Quanterix.
F2 Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration (as defined in the Merger Agreement) was automatically terminated and cancelled for no consideration.